Compare SUPN & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | INSP |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2014 | 2018 |
| Metric | SUPN | INSP |
|---|---|---|
| Price | $26.85 | $66.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 18 |
| Target Price | $60.50 | ★ $69.44 |
| AVG Volume (30 Days) | ★ 1.7M | 698.7K |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8100.00 | 179.43 |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $1,239,000,000.00 | $82,050,000.00 |
| Revenue This Year | $23.01 | N/A |
| Revenue Next Year | $15.28 | $2.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.29 | ★ 62.18 |
| 52 Week Low | $26.74 | $38.91 |
| 52 Week High | $59.68 | $147.03 |
| Indicator | SUPN | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 19.93 | 45.26 |
| Support Level | N/A | $58.79 |
| Resistance Level | $51.59 | $73.69 |
| Average True Range (ATR) | 2.21 | 2.87 |
| MACD | -1.14 | -0.82 |
| Stochastic Oscillator | 8.37 | 48.97 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.